Join
Live feed
·
PRReleasevia Quantisnow
HUTCHMED (China) Limited logo

HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

ByQuantisnow·Wall Street's wire, on your screen.
HCM· HUTCHMED (China) Limited
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track HCM (HUTCHMED (China) Limited) and more on Quantisnow.